September 9, 2019
Boehringer nets FDA’s approval for Ofev for slowing decline in pulmonary function with SSc-ILD patients
@Boehringer has the first FDA-approved therapy to slow the rate of decline in pulmonary function for systemic sclerosis-associated interstitial lung disease